Home >> Arcyriaflavin A
Related Products
Arcyriaflavin A cdk4/cyclin D1 inhibitor

Catalog No.B7063
Size Price Stock Qty
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors


Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & MSDS

View current batch:

Chemical structure

Arcyriaflavin A

Arcyriaflavin A Dilution Calculator

Concentration (start)
Volume (start)
Concentration (final)
Volume (final)


Arcyriaflavin A Molarity Calculator



Chemical Properties

Cas No. 118458-54-1 SDF Download SDF
Chemical Name 12,13-dihydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione
Canonical SMILES O=C(C1=C2C(NC3=CC=CC=C23)=C4NC5=CC=CC=C5C4=C16)NC6=O
Formula C20H11N3O2 M.Wt 325.32
Solubility Soluble in DMSO > 10 mM Storage Store at -20°C
Physical Appearance Orange solid Shipping Condition Evaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.


IC50: 0.2 μM for HCMV [1], 0.14 μM for D1–CDK4 [2]

The natural product Arcyriaflavin A, unsubstituted indolocarbazole, was a potent selective inhibitor of human cytomegalovirus (HCMV) replication. HCMV infection is typically unnoticed in healthy people, but can be life-threatening for the immunocompromised.

In vitro: Arcyriaflavin A is a potent, selective inhibitor of HCMV replication in cell culture, and the anti-HCMV activity appeared no relation to the inhibition of protein kinase C. The imide NH was identified to be essential for anti-HCMV activity [1]. Arcyriaflavin A also has been showed the inhibitory activity against D1/CDK4 with a IC50 of 59 nM. Based on X-ray co-crystal structure of staurosporine and the human CDK2, the acidic proton of the maleimide moiety and the carbonyl group play critical roles by acting as a hydrogen bond donor and acceptor in the ATP binding pocket of CDK2 [2].

In vivo: So far, no in vivo study has been conducted.

Clinical trial: So far, no clinical study has been conducted.

[1] Slater MJ, Cockerill S, Baxter R, Bonser RW, Gohil K, Gowrie C, Robinson JE, Littler E, Parry N, Randall R, Snowden W.  Indolocarbazoles: potent, selective inhibitors of human cytomegalovirus replication. Bioorg Med Chem. 1999 Jun;7(6):1067-74.
[2] Zhu G, Conner S, Zhou X, Shih C, Brooks HB, Considine E, Dempsey JA, Ogg C, Patel B, Schultz RM, Spencer CD, Teicher B, Watkins SA.  Synthesis of quinolinyl/isoquinolinyl[a]pyrrolo [3,4-c] carbazoles as cyclin D1/CDK4 inhibitors. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1231-5.